Ronald F van Vollenhoven

Summary

Affiliation: Karolinska Hospital
Country: Sweden

Publications

  1. ncbi Increased DHEAS levels in patients with rheumatoid arthritis after treatment with tumor necrosis factor antagonists: evidence for improved adrenal function
    Sofia Ernestam
    Department of Rheumatology, Division of Clinical Chemistry, Karolinska Institute at Karolinska University Hospital, Huddinge, Stockholm, Sweden
    J Rheumatol 34:1451-8. 2007
  2. ncbi CD25brightCD4+ regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease
    Duojia Cao
    Rheumatology Unit, Department of Medicine at Karolinska Hospital, Karolinska Institutet, Stockholm, Sweden
    Arthritis Res Ther 6:R335-46. 2004
  3. ncbi Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense
    R van Vollenhoven
    Department of Rheumatology, Karolinska Hospital, 17176 Stockholm, Sweden
    Ann Rheum Dis 62:1195-8. 2003
  4. ncbi Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious
    Ronald F van Vollenhoven
    Department of Rheumatology, Karolinska Hospital, Stockholm, Sweden
    Arthritis Res Ther 5:R347-51. 2003
  5. ncbi Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone
    R F van Vollenhoven
    Department of Rheumatology, Karolinska Hospital, Stockholm, Sweden
    Scand J Rheumatol 33:423-7. 2004
  6. ncbi Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?
    Johan Askling
    Department of Medicine Solna, Karolinska University Hospital at Solna and Karolinska Institutet, Stockholm, Sweden
    Arthritis Rheum 60:3180-9. 2009
  7. ncbi Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial
    Ronald F van Vollenhoven
    Unit for Clinical Therapy Research, Inflammatory Diseases, Karolinska Institute, Stockholm, Sweden
    Lancet 379:1712-20. 2012
  8. ncbi Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration
    Katerina Chatzidionysiou
    Department of Rheumatology, Karolinska University Hospital, Stockholm, Sweden
    Ann Rheum Dis 71:374-7. 2012
  9. ncbi In early rheumatoid arthritis, patients with a good initial response to methotrexate have excellent 2-year clinical outcomes, but radiological progression is not fully prevented: data from the methotrexate responders population in the SWEFOT trial
    Hamed Rezaei
    Unit of Clinical Therapy Research, Inflammatory Diseases, The Karolinska Institute, Stockholm, Sweden
    Ann Rheum Dis 71:186-91. 2012
  10. ncbi Systemic TNF blockade does not modulate synovial expression of the pro-inflammatory mediator HMGB1 in rheumatoid arthritis patients--a prospective clinical study
    Erik Sundberg
    Department of Woman and Child Health, Pediatric Rheumatology Research Unit, Karolinska Institutet Karolinska University Hospital, Stockholm, Sweden
    Arthritis Res Ther 10:R33. 2008

Detail Information

Publications36

  1. ncbi Increased DHEAS levels in patients with rheumatoid arthritis after treatment with tumor necrosis factor antagonists: evidence for improved adrenal function
    Sofia Ernestam
    Department of Rheumatology, Division of Clinical Chemistry, Karolinska Institute at Karolinska University Hospital, Huddinge, Stockholm, Sweden
    J Rheumatol 34:1451-8. 2007
    ..To determine if major reduction of inflammation with longterm tumor necrosis factor (TNF) antagonist treatment has any influence on the adrenal and gonadal axes in patients with rheumatoid arthritis (RA)...
  2. ncbi CD25brightCD4+ regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease
    Duojia Cao
    Rheumatology Unit, Department of Medicine at Karolinska Hospital, Karolinska Institutet, Stockholm, Sweden
    Arthritis Res Ther 6:R335-46. 2004
    ..Their capacity to suppress both proliferation and cytokine secretion might contribute to a dampening of local inflammatory processes...
  3. ncbi Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense
    R van Vollenhoven
    Department of Rheumatology, Karolinska Hospital, 17176 Stockholm, Sweden
    Ann Rheum Dis 62:1195-8. 2003
    ..When one TNFalpha blocker (etanercept or infliximab) has failed, to determine whether it makes sense to treat patients with the other...
  4. ncbi Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious
    Ronald F van Vollenhoven
    Department of Rheumatology, Karolinska Hospital, Stockholm, Sweden
    Arthritis Res Ther 5:R347-51. 2003
    ..Other disease outcomes showed non-significant trends in the same direction. These data suggest that the combination of etanercept plus MTX is clinically more efficacious than etanercept alone...
  5. ncbi Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone
    R F van Vollenhoven
    Department of Rheumatology, Karolinska Hospital, Stockholm, Sweden
    Scand J Rheumatol 33:423-7. 2004
    ..The monoclonal anti-B cell antibody rituximab (Rituxin, Mabthera) may be of benefit in antibody-driven diseases, including systemic lupus erythematosus (SLE) nephritis...
  6. ncbi Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?
    Johan Askling
    Department of Medicine Solna, Karolinska University Hospital at Solna and Karolinska Institutet, Stockholm, Sweden
    Arthritis Rheum 60:3180-9. 2009
    ..To determine the short-term and medium-term risks of cancer in patients receiving anti-tumor necrosis factor alpha (anti-TNFalpha) therapies that have proven effective in the treatment of chronic inflammatory conditions...
  7. ncbi Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial
    Ronald F van Vollenhoven
    Unit for Clinical Therapy Research, Inflammatory Diseases, Karolinska Institute, Stockholm, Sweden
    Lancet 379:1712-20. 2012
    ..Here we report the 2 year follow-up assessment...
  8. ncbi Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration
    Katerina Chatzidionysiou
    Department of Rheumatology, Karolinska University Hospital, Stockholm, Sweden
    Ann Rheum Dis 71:374-7. 2012
    ..To compare the effectiveness and safety of rituximab alone or in combination with either methotrexate or leflunomide...
  9. ncbi In early rheumatoid arthritis, patients with a good initial response to methotrexate have excellent 2-year clinical outcomes, but radiological progression is not fully prevented: data from the methotrexate responders population in the SWEFOT trial
    Hamed Rezaei
    Unit of Clinical Therapy Research, Inflammatory Diseases, The Karolinska Institute, Stockholm, Sweden
    Ann Rheum Dis 71:186-91. 2012
    ..To investigate the 2-year clinical and radiological outcomes of patients with early rheumatoid arthritis (RA; symptom duration <1 year) who had initially responded well to methotrexate monotherapy...
  10. ncbi Systemic TNF blockade does not modulate synovial expression of the pro-inflammatory mediator HMGB1 in rheumatoid arthritis patients--a prospective clinical study
    Erik Sundberg
    Department of Woman and Child Health, Pediatric Rheumatology Research Unit, Karolinska Institutet Karolinska University Hospital, Stockholm, Sweden
    Arthritis Res Ther 10:R33. 2008
    ..It was, therefore, decided to investigate whether treatment based on TNF blockade in rheumatoid arthritis (RA) affects the expression of synovial HMGB1...
  11. ncbi Clinical responses to tumor necrosis factor alpha antagonists do not show a bimodal distribution: data from the Stockholm tumor necrosis factor alpha followup registry
    Ronald F van Vollenhoven
    Karolinska Hospital, Stockholm, Sweden
    Arthritis Rheum 48:1500-3. 2003
    ....
  12. ncbi Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial
    Saedis Saevarsdottir
    Rheumatology Unit, Department of Medicine, Karolinska University Hospital, 17176 Stockholm, Sweden
    Ann Rheum Dis 70:469-75. 2011
    ..To identify predictors of response to methotrexate (MTX) in early rheumatoid arthritis (RA)...
  13. ncbi Patterns of interaction between genetic and nongenetic attributes and methotrexate efficacy in rheumatoid arthritis
    Thierry Dervieux
    Exagen Diagnostics, Inc, Albuquerque, New Mexico, USA
    Pharmacogenet Genomics 22:1-9. 2012
    ..We sought to elucidate architecture of methotrexate response in three cohorts of patients with RA treated with methotrexate...
  14. ncbi Reduction of temporomandibular joint pain after treatment with a combination of methotrexate and infliximab is associated with changes in synovial fluid and plasma cytokines in rheumatoid arthritis
    Sigvard Kopp
    Department of Clinical Oral Physiology, Institute of Odontology, Karolinska Institutet, Department of Rheumatology, Huddinge, Sweden
    Cells Tissues Organs 180:22-30. 2005
    ..In conclusion, systemic treatment with a combination of infliximab and methotrexate reduces TMJ pain in RA in association with an increase in anti-inflammatory cytokines and receptors in synovial fluid and plasma...
  15. ncbi Evaluation of hand bone loss by digital X-ray radiogrammetry as a complement to clinical and radiographic assessment in early rheumatoid arthritis: results from the SWEFOT trial
    Hamed Rezaei
    Unit of Clinical Therapy Research, Inflammatory Diseases ClinTRID, The Karolinska Institute, Stockholm, SE 171 76, Sweden
    BMC Musculoskelet Disord 14:79. 2013
    ....
  16. ncbi Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response
    Ronald F van Vollenhoven
    Unit for Clinical Therapy Research, Inflammatory Diseases, The Karolinska Institute, Stockholm, Sweden
    Ann Rheum Dis 71:1343-9. 2012
    ..To identify factors that predict response to belimumab treatment in the phase 3 BLISS trials of autoantibody-positive systemic lupus erythematosus (SLE) and further analyse clinical efficacy in various patient subsets...
  17. ncbi Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists
    Johan Askling
    Clinical Epidemiology Unit, Department of Medicine, Karolinska University Hospital, Stockholm, Sweden
    Ann Rheum Dis 66:1339-44. 2007
    ..An observational cohort study was performed using prospectively collected data from the Swedish Biologics Register (ARTIS) and other national Swedish registers...
  18. ncbi Improvement in work place and household productivity for patients with early rheumatoid arthritis treated with adalimumab plus methotrexate: work outcomes and their correlations with clinical and radiographic measures from a randomized controlled trial co
    Ronald F van Vollenhoven
    Karolinska University Hospital and Karolinska Institute, Stockholm, Sweden
    Arthritis Care Res (Hoboken) 62:226-34. 2010
    ..We also determined baseline predictors of household and work place outcomes...
  19. ncbi The selective estrogen receptor alpha agonist Org 37663 induces estrogenic effects but lacks antirheumatic activity: a phase IIa trial investigating efficacy and safety of Org 37663 in postmenopausal female rheumatoid arthritis patients receiving stable b
    Ronald F van Vollenhoven
    Karolinska Institute, Stockholm, Sweden
    Arthritis Rheum 62:351-8. 2010
    ..We undertook this study to determine the effects of the selective estrogen receptor alpha (ERalpha) agonist Org 37663 in patients with RA, in terms of both its estrogenic effects and its ability to ameliorate disease activity...
  20. ncbi Cost-effectiveness of real-world infliximab use in patients with rheumatoid arthritis in Sweden
    Ingrid Lekander
    i3 Innovus and MMC, LIME, Stockholm, Sweden
    Int J Technol Assess Health Care 26:54-61. 2010
    ....
  21. ncbi Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis
    Iva Gunnarsson
    Department of Rheumatology, Karolinska University Hospital at Solna, Stockholm, Sweden
    Arthritis Rheum 56:1263-72. 2007
    ..The purpose of this study was to investigate the histopathologic and clinical effects of combination treatment with rituximab and cyclophosphamide (CYC) in patients with CYC-resistant proliferative lupus nephritis...
  22. ncbi Low-dose glucocorticoid therapy decreases risk for treatment-limiting infusion reaction to infliximab in patients with rheumatoid arthritis
    Jenny Augustsson
    Department of Rheumatology, Karolinska University Hospital Solna, 171 76 Stockholm, Sweden
    Ann Rheum Dis 66:1462-6. 2007
    ..Treatment-limiting infusion reactions to infliximab have not been fully explained in rheumatoid arthritis patients. Our main objective is to investigate the role of daily oral glucocorticoids use on such reactions...
  23. ncbi Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials
    Ronald F van Vollenhoven
    Karolinska University Hospital, Stockholm, Sweden
    J Rheumatol 37:558-67. 2010
    ..To evaluate the longterm safety of rituximab in clinical trials in patients with rheumatoid arthritis (RA)...
  24. ncbi Treatment of rheumatoid arthritis: state of the art 2009
    Ronald F van Vollenhoven
    Rheumatology Unit, Department of Medicine, The Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden
    Nat Rev Rheumatol 5:531-41. 2009
    ....
  25. ncbi Synovial expression of IL-15 in rheumatoid arthritis is not influenced by blockade of tumour necrosis factor
    Sofia Ernestam
    Department of Rheumatology, Karolinska University Hospital, S 141 86 Stockholm, Sweden
    Arthritis Res Ther 8:R18. 2006
    ..Consequently, we propose that IL-15 should remain as a therapeutic target in RA, regardless of the response to TNF blockade...
  26. ncbi Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries
    Katerina Chatzidionysiou
    Department of Rheumatology, Karolinska University Hospital, Stockholm, Sweden
    Ann Rheum Dis 70:1575-80. 2011
    ..To assess the 6-month effectiveness of the first rituximab (RTX) course in rheumatoid arthritis (RA) and to identify possible predictors of response...
  27. ncbi Patient-reported 28 swollen and tender joint counts accurately represent RA disease activity and can be used to assess therapy responses at the group level
    Jenny Riazzoli
    Department of Medicine, Rheumatology Unit, Karolinska Institute, Karolinska University Hospital Solna, Stockholm, Sweden
    Rheumatology (Oxford) 49:2098-103. 2010
    ....
  28. ncbi Sex differences in rheumatoid arthritis: more than meets the eye
    Ronald F van Vollenhoven
    Department of Rheumatology, Karolinska University Hospital, 17176 Stockholm, Sweden
    BMC Med 7:12. 2009
    ....
  29. ncbi New and future agents in the treatment of rheumatoid arthritis
    Ronald F van Vollenhoven
    Department of Rheumatology, The Karolinska Institute, Stockholm 17176, Sweden
    Discov Med 9:319-27. 2010
    ....
  30. ncbi Skewed distribution of proinflammatory CD4+CD28null T cells in rheumatoid arthritis
    Andreas E R Fasth
    Rheumatology Unit, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Arthritis Res Ther 9:R87. 2007
    ..Together these data imply a primary role for CD4+CD28null T cells in manifestations elsewhere than in the joints of patients with HCMV-seropositive rheumatoid arthritis...
  31. ncbi Evidence for immunostimulatory effects of intramuscular gold in patients with rheumatoid arthritis: correlation with skin reactions
    Sofia Ernestam
    Department of Rheumatology, Huddinge University Hospital, Karolinska Institute, Stockholm, Sweden
    J Rheumatol 30:1748-55. 2003
    ..In this prospective study we investigated cytokine production in peripheral blood from patients with RA during treatment with GSTM...
  32. ncbi Biologicals for the treatment of systemic lupus erythematosus?
    Iva Gunnarsson
    Department of Medicine, Rheumatology Unit, Karolinska University Hospital, The Karolinska Institute, Stockholm, Sweden
    Ann Med 44:225-32. 2012
    ..We may be at the threshold of a new era in SLE therapeutics...
  33. ncbi Observational studies: a valuable source for data on the true value of RA therapies
    Ronald F van Vollenhoven
    Clinical Therapy Research, The Karolinska Institute, Stockholm, Sweden
    Clin Rheumatol 30:S19-24. 2011
    ..Observational studies are truly an underappreciated and valuable source of data on the real value of anti-rheumatic therapies, and these data are essential for making sound decisions regarding coverage and reimbursement...
  34. ncbi Fcgamma receptor type IIIA genotype and response to tumor necrosis factor alpha-blocking agents in patients with rheumatoid arthritis
    Alf Kastbom
    Linkoping University, Linkoping, Sweden
    Arthritis Rheum 56:448-52. 2007
    ....
  35. ncbi Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis
    Anca Irinel Catrina
    Rheumatology Research Laboratory, Karolinska University Hospital, Karolinska Institutet, S 17176 Stockholm, Sweden
    Arthritis Rheum 54:76-81. 2006
    ..In order to add to such knowledge, we investigated the effect of anti-TNF therapy on the expression of osteoprotegerin (OPG) and receptor activator of NF-kappaB ligand (RANKL) in synovial tissue...
  36. ncbi [TNF blockade in rheumatoid arthritis can cause severe fibrosing alveolitis. Six case reports]
    Birgitta Tengstrand
    Reumatologiska kliniken, Karolinska Universitetssjukhuset Huddinge, SE-141 86 Stockholm, Sweden
    Lakartidningen 102:3788-90, 3793. 2005
    ..Age above 60 years and previous lung fibrosis appear to be risk factors for developing fibrosing alveolitis in RA patients treated with TNF-blockade...